The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
Ajanta Pharma's recent agreement to market semaglutide across emerging markets has the potential to influence its medium-term growth. The company's established presence and strategic focus on branded generics contribute to a positive outlook. Financial analysts predict substantial revenue increases in the coming years.
This article explores the potential benefits of increasing fiber intake, known as "fibermaxxing," for improved digestion and energy. A personal two-week experiment reveals the ease and impact of incorporating more fiber-rich foods into one's diet, supported by expert nutritionist recommendations.
India's healthcare roadmap for 2026 prioritizes enhancing drug quality, expanding digital health services, and addressing critical public health issues such as tuberculosis and obesity. The government aims to transform India into a global life sciences hub by focusing on innovation and stringent quality standards.
The approval of new GLP-1 weight-loss pills is anticipated to reshape the food industry, potentially leading to widespread product overhauls. Analysts foresee that the availability of these medications, particularly in pill form, will prompt significant shifts in consumer demand and industry responses.
The healthcare landscape will undergo significant changes in 2026. Negotiated Medicare drug prices offer relief to some, but the expiration of Affordable Care Act tax credits and Medicaid uncertainties will increase costs for others.
Weight-loss drugs, particularly those mimicking GLP-1, have gained significant traction. This article delves into their functionality, efficacy, side effects, accessibility challenges, and the emergence of more accessible pill versions.
This article examines differing viewpoints on contemporary health issues. It delves into pollution in Delhi, the increasing popularity of GLP-1 drugs, and the potential for dopamine addiction in today's society.
Coverage remains a major hurdle for patients seeking GLP-1 medications for obesity, with Medicare and many private insurers not including them. However, two recent events could change the legal landscape: reduced medication costs and the WHO's classification of obesity as a chronic condition.
A survey indicates many worry about weight gain during Christmas. For Mounjaro users, managing holiday meals can be especially challenging. A doctor provides advice on enjoying Christmas dinner without compromising progress, including intermittent fasting and mindful eating strategies.
